Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Common Equity (2016 - 2025)

Fortress Biotech has reported Common Equity over the past 13 years, most recently at $49.9 million for Q4 2025.

  • Quarterly results put Common Equity at $49.9 million for Q4 2025, up 3133.64% from a year ago — trailing twelve months through Dec 2025 was $49.9 million (up 3133.64% YoY), and the annual figure for FY2025 was $49.9 million, up 3133.64%.
  • Common Equity for Q4 2025 was $49.9 million at Fortress Biotech, down from $55.9 million in the prior quarter.
  • Over the last five years, Common Equity for FBIO hit a ceiling of $248.3 million in Q2 2021 and a floor of -$15.9 million in Q2 2023.
  • Median Common Equity over the past 5 years was $43.6 million (2025), compared with a mean of $77.9 million.
  • Biggest five-year swings in Common Equity: crashed 203.59% in 2024 and later surged 3133.64% in 2025.
  • Fortress Biotech's Common Equity stood at $225.9 million in 2021, then plummeted by 77.85% to $50.0 million in 2022, then crashed by 96.83% to $1.6 million in 2023, then crashed by 203.59% to -$1.6 million in 2024, then surged by 3133.64% to $49.9 million in 2025.
  • The last three reported values for Common Equity were $49.9 million (Q4 2025), $55.9 million (Q3 2025), and $37.4 million (Q2 2025) per Business Quant data.